Ra Medical Systems (RMED) Misses Q3 EPS by 24c

Ra Medical Systems (NYSE: RMED) reported Q3 EPS of ($0.59), $0.24 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $2.06 million versus the consensus estimate of $2 million.

“The third quarter of 2018 was pivotal in our Company’s history as we commenced trading on the New York Stock Exchange after pricing our initial public offering (IPO). With increased capital, we are focused on growing our business by increasing our direct sales force and ramping up our marketing efforts,” said Dean Irwin, Chief Executive Officer, Ra Medical Systems.

“With regulatory clearance in the U.S. and Europe, we are dedicating resources to increase both the awareness and adoption of our DABRA system to treat Peripheral Artery Disease (PAD), a disease affecting approximately 17.6 million people in the United States,” concluded Mr. Irwin.

For earnings history and earnings-related data on Ra Medical Systems (RMED) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Stantec (STN) Tops Q2 EPS by 47c
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance